Daiichi Company Profile
✉ Email this page to a colleague
What is the competitive landscape for DAIICHI, and what generic alternatives to DAIICHI drugs are available?
DAIICHI has four approved drugs.
There are twenty-five US patents protecting DAIICHI drugs.
There are three hundred and twenty-four patent family members on DAIICHI drugs in forty-five countries and twenty-eight supplementary protection certificates in sixteen countries.
Summary for Daiichi
| International Patents: | 324 |
| US Patents: | 25 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 4 |
| Patent Litigation for Daiichi: | See patent lawsuits for Daiichi |
| PTAB Cases with Daiichi as patent owner: | See PTAB cases with Daiichi as patent owner |
Drugs and US Patents for Daiichi
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Daiichi Sankyo Inc | SAVAYSA | edoxaban tosylate | TABLET;ORAL | 206316-002 | Jan 8, 2015 | RX | Yes | No | 7,365,205 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Daiichi Sankyo Inc | VANFLYTA | quizartinib dihydrochloride | TABLET;ORAL | 216993-001 | Jul 20, 2023 | RX | Yes | No | 8,357,690 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Daiichi Sankyo Inc | TURALIO | pexidartinib hydrochloride | CAPSULE;ORAL | 211810-002 | Oct 14, 2022 | RX | Yes | No | 9,802,932 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Daiichi Sankyo Inc | VANFLYTA | quizartinib dihydrochloride | TABLET;ORAL | 216993-001 | Jul 20, 2023 | RX | Yes | No | 7,968,543 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Daiichi Sankyo Inc | SAVAYSA | edoxaban tosylate | TABLET;ORAL | 206316-001 | Jan 8, 2015 | RX | Yes | No | 9,149,532 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Daiichi Sankyo Inc | TURALIO | pexidartinib hydrochloride | CAPSULE;ORAL | 211810-001 | Aug 2, 2019 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Daiichi Sankyo Inc | VANFLYTA | quizartinib dihydrochloride | TABLET;ORAL | 216993-001 | Jul 20, 2023 | RX | Yes | No | 8,836,218 | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Daiichi
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Daiichi | FLOXIN OTIC | ofloxacin | SOLUTION/DROPS;OTIC | 020799-001 | Dec 16, 1997 | 5,401,741 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for DAIICHI drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 15 mg, 30 mg and 60 mg | ➤ Subscribe | 2019-01-28 |
International Patents for Daiichi Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 4610668 | ⤷ Subscribe |
| Japan | 2018516880 | ⤷ Subscribe |
| Taiwan | I409064 | ⤷ Subscribe |
| European Patent Office | 2343290 | ⤷ Subscribe |
| Nicaragua | 200900093 | ⤷ Subscribe |
| South Korea | 20120000567 | ⤷ Subscribe |
| Spain | 2389027 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Daiichi Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1405852 | 122015000077 | Germany | ⤷ Subscribe | PRODUCT NAME: EDOXABAN, DESSEN SALZ, DESSEN SOLVAT, ODER DESSEN N-OXID, INSBESONDERE EDOXABANTOSILAT; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619 |
| 1429780 | SPC/GB12/058 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003 |
| 1405852 | 300760 | Netherlands | ⤷ Subscribe | PRODUCT NAME: EDOXABAN, EEN ZOUT DAARVAN, EEN SOLVAAT DAARVAAN OF EEN N-OXIDE DAARVAN, IN HET BIJZONDER EDOXABAN TOSYLAAT; REGISTRATION NO/DATE: EU/1/15/993 20150619 |
| 1405852 | CA 2015 00052 | Denmark | ⤷ Subscribe | PRODUCT NAME: EDOXABAN, HERUNDER EDOXABAN TOSILATE; REG. NO/DATE: EU/1/15/993/001-028 20150623 |
| 2429524 | CA 2024 00013 | Denmark | ⤷ Subscribe | PRODUCT NAME: QUIZARTINIB; REG. NO/DATE: EU/1/23/1768 20231107 |
| 2140867 | PA2018005 | Lithuania | ⤷ Subscribe | PRODUCT NAME: EDOKSABANAS, JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, ARBA BET KURIO IS JU HIDRATAS, YPAC EDOKSABANO P-TOLUENSULFONATO MONOHIDRATAS; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619 |
| 1405852 | 92835 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: EDOXABAN, UN DE SES SELS, UN DE SES SOLVATES OU UN N-OXYDE DE CELUI-CI, EN PARTICULIER UN TOSYLATE D EDOXABAN. FIRST REGISTRATION: 20150619 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
